Abstracts tagged "Lupus nephritis"

Abstract Number: 2958 • 2018 ACR/ARHP Annual Meeting
Multi-Site Study Evaluating Performance on Lupus Nephritis Quality Measures
Ishita Aggarwal¹, Laura Trupin², Jing Li³, Lisa Gaynon⁴, Nancy Liu⁵, Chris Schlechter⁶, Louise Murphy⁷, Maria Dall'Era⁶ and Jinoos Yazdany⁶, ¹University of California San Francisco, San Francisco, CA, ²Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ³Medicine, UC San Francisco, San Francisco, CA, ⁴Internal Medicine, California Pacific Medical Center, San Francisco, CA, ⁵Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁶University of California, San Francisco, San Francisco, CA, ⁷Arthritis Program, Centers for Disease Control and Prevention, Atlanta, GA
Background/Purpose: Lupus nephritis (LN), seen in up to 60% of individuals with SLE, progresses to end stage renal failure in 10-30% of patients within 15…
Abstract Number: 461 • 2018 ACR/ARHP Annual Meeting
Ofatumumab Use in Childhood-Onset Systemic Lupus Erythematosus: A Single-Center Experience
Anna Carmela Sagcal-Gironella¹, Eyal Muscal², Andrea A. Ramirez¹, Monica Marcus³, Miriah Gillispie¹, William Blaine Lapin¹ and Marietta M. De Guzman⁴, ¹Department of Pediatrics, Division of Immunology, Allergy, and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ²Department of Pediatrics, Division of Immunology, Allergy, and Rheumatology, Baylor College of Medicine, Houston, TX, ³Deaprtment of Pediatrics, Division of Immunology, Allergy, and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ⁴Pediatric Immunology, Allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Ofatumumab is a fully human anti-CD20 monoclonal antibody that has been approved for the treatment of chronic lymphocytic leukemia. It has been increasingly used…
Abstract Number: 464 • 2018 ACR/ARHP Annual Meeting
The Long Term Outcomes in Chinese Children Diagnosed with Systemic Lupus Erythematosus and Biopsy Proven Lupus Nephritis – a 18-Year Cohort
Grace Chiang^1,2, Sik Nin Wong³, Clara Law⁴, Kwok Piu Lee⁵, Cheuk Chun Szeto⁶, Chi Chiu Mok⁷, Lai-Shan Tam⁸ and Ting Fan Leung⁹, ¹Paediatrics, Prince of Wales Hospital, The Chinese University of Hong Kong, Sha Tin, Hong Kong, ²Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ³Paediatrics and Adolescent Medicine, Tune Mun Hospital, Hong Kong, Hong Kong, ⁴Medicine and Therapeutics, Alice Ho Miu Ling Nethersole Hospital, Hong Kong, Hong Kong, ⁵Paediatrics and Adolescent Medicine, Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong, ⁶Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ⁷Medicine and Geriatrics, Tune Mun Hospital, Hong Kong, Hong Kong, Hong Kong, ⁸Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, Hong Kong, Hong Kong, ⁹Paediatrics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: Renal disease occurs in 50-70% of all childhood onset systemic lupus erythematosus (cSLE). The prevalence of LN is higher in children and the manifestations…
Abstract Number: 735 • 2018 ACR/ARHP Annual Meeting
Serum Albumin at One Year Predicts Long-Term Renal Outcome
Vinicius Domingues¹, Daniel Goldman², Laurence S Magder³ and Michelle Petri², ¹Medicine, New York University School of Medicine, New York, NY, ²Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, ³Epidemiology and Public health, University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: Lupus nephritis remains a major cause of morbidity/mortality in SLE. Our cohort has shown that 20% of SLE patients with lupus nephritis onset…
Abstract Number: 739 • 2018 ACR/ARHP Annual Meeting
Urine and Plasma Soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1) Differentially Correlates with Renal and Non-Renal Systemic Lupus Erythematosus (SLE): A Prospective, Case-Control Study
Yair Molad^1,2, Mohammad Egbaria³, Ariela Dortort-Lazar^4,5, Elisheva Pokroy-Shapira^3,5, Shirly Oren⁴, Yonatan Edel^3,5 and Vitaly Kliminski^5,6, ¹Rheumatology Unit, Rabin Medical Center - Beilinson Campus, Petah-Tiqva, Israel, ²Felsenstein Medical Research Center, Sackler Faculty of Medicine, Tel Aviv University, Petah Tikva, Israel, ³Rheumatology Unit, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel, ⁴Rheumatology Unit, Beilinson Hospital, Rabin Medical Center, Petach Tikva, Israel, ⁵Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ⁶Laboratory of Inflammation Research, Felsenstein Medical Research Center, Rabin Medical Center, Petach Tikva, Israel
Background/Purpose: Elevated levels of sTREM-1 have been previously found in patients with SLE. A prospective, case-control, longitudinal study aimed to assess the value of urinary…
Abstract Number: 749 • 2018 ACR/ARHP Annual Meeting
Is Lupus Nephritis Onset Delayed in Older Caucasian Females with Less Aggressive Pathology?
Cristina Arriens¹, Sixia Chen², David Karp³, Ramesh Saxena⁴, Joan T. Merrill¹ and Judith A. James⁵, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Rheumatic Diseases Division, UT Southwestern Medical Center, Dallas, TX, ⁴Nephrology Division, UT Southwestern Medical Center, Dallas, TX, ⁵Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Lupus Nephritis (LN) usually presents within 5 years of SLE diagnosis, however the minority of patients with late-occurring nephritis are poorly characterized. Factors associated…
Abstract Number: 763 • 2018 ACR/ARHP Annual Meeting
Comparison of Clinical Characteristics and Outcome between Isolated and Classic Lupus Nephritis
Kubra Bugdayli¹, Cynthia S. Crowson², Ladan Zand³, Mariam P. Alexander⁴, Lynn D. Cornell⁴ and Vaidehi R. Chowdhary⁵, ¹Department of Internal Medicine, Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, MN, ²Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Nephrology and Hypertension, Mayo Clinic, Rochester, MN, ⁴Anatomic Pathology, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁵Internal Medicine, Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN
Comparison of clinical characteristics and outcome between isolated and classic lupus nephritisBackground/Purpose: Lupus nephritis (LN) is a serious manifestation of systemic lupus erythematosus (SLE). Rarely,…
Abstract Number: 702 • 2017 ACR/ARHP Annual Meeting
Positive Direct Coombs’ Test in the Absence of Hemolytic Anemia Predicts High Disease Activity and Poor Renal Response in Systemic Lupus Erythematosus
Hironari Hanaoka, Harunobu Iida, Tomofumi Kiyokawa, Yukiko Takakuwa and Kimito Kawahata, Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: Direct Coombs' test in the absence of hemolytic anemia was newly included in the immunologic criterion of the SLICC/ACR 2012 criteria for SLE. Since…
Abstract Number: 1843 • 2017 ACR/ARHP Annual Meeting
Serum Albumin at 12 Months Post Biopsy Has Excellent Sensitivity and Specificity for Favorable 4 Year Renal Outcome in Lupus Nephritis (LN)
Vinicius Domingues¹, Nicole Bornkamp¹, Benjamin A. Levinson², Judith D. Goldberg², Jill P. Buyon¹ and H. Michael Belmont¹, ¹Medicine, New York University School of Medicine, New York, NY, ²Population Health, New York University School of Medicine, New York, NY
Background/Purpose: LN is a common, deleterious manifestation of systemic lupus erythematosus (SLE) and despite recent advances in treatment remains the most significant end organ injury…
Abstract Number: 1920 • 2017 ACR/ARHP Annual Meeting
Tacrolimus Induces Remission in Refractory and Relapsing Lupus Nephritis By Decreasing P-Glycoprotein Expression and Function on Peripheral Blood Lymphocytes
Vikas Gupta, Sukesh Edavalath, Mohit Kumar Rai, Harshit Singh, Saurabh Chaturvedi and Vikas Agarwal, Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: About 15-30% of Lupus Nephritis (LN) patients do not respond to first-line immunosuppressive therapy. P-glycoprotein (P-gp) mediated efflux of corticosteroids (CS) may contribute to…
Abstract Number: 2570 • 2017 ACR/ARHP Annual Meeting
The Functional Consequence of Human (hu)TLR8 on Macrophage Immunometabolism and Renal Inflammation in Murine Systemic Lupus Erythematosus
Naomi I. Maria¹, Megan Woods², Shani Martinez³, Weiqing Huang⁴ and Anne Davidson⁴, ¹Center for Autoimmune and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY, ²Center for Autoimmunity and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY, ³Feinstein Institute for Medical Research, Manhasset, NY, ⁴Autoimmunity and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: Infiltrating macrophages are one of the hallmarks of renal inflammation and kidney damage in lupus nephritis. Increasing evidence suggests the crucial role of cell-specific…
Abstract Number: 2603 • 2017 ACR/ARHP Annual Meeting
Induction of Lupus Nephritisin in Real Situation: Cyclophosphamide or Mycophenolate Mofetil?
Gabriela Munhoz¹, Maira Lacerda¹, Michelle Lopes¹, Eduardo Ferreira Borba¹, Luciana Seguro² and Eloisa Bonfa³, ¹Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Rheumatology Divison, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Low-dose intravenous cyclophosphamide (Euro-lupus) and Mycophenolate mofetil (MMF) are well established in lupus nephritis induction therapy, but there are few studies comparing both treatments.…
Abstract Number: 2608 • 2017 ACR/ARHP Annual Meeting
Tacrolimus in Non-Asian Systemic Lupus Erythematosus Patients: A Real-Life Experience from Three European Centers
Chiara Tani¹, Miguel Martin-Cascon², Mériem Belhocine³, Roberta Vagelli¹, Chiara Stagnaro⁴, Guillermo Ruiz-Irastorza⁵, Nathalie Costedoat-Chalumeau³ and Marta Mosca¹, ¹Rheumatology Unit, University of Pisa, Pisa, Italy, ²Autoimmune Diseases Research Unit, BioCruces, Hospital Universitario Cruces, Barakaldo, Spain, ³Service de médecine interne Pôle médecine, Hôpital Cochin, Centre de référence maladies auto-immunes et systémiques rares de l’île de France, Paris, France, ⁴Rheumatology Unit, University of Pisa, PISA, Italy, ⁵Autoimmune Diseases Research Unit, BioCruces, Hospital Universitario Cruces, Baracaldo, Spain
Background/Purpose: there is no consensus on the use of Tacrolimus (TAC) in patients with SLE; clinical studies on TAC, including all the RCT, are mostly…
Abstract Number: 2624 • 2017 ACR/ARHP Annual Meeting
A Renal Biopsy Should Not Delay Treatment Initiation in Suspected Lupus Nephritis
Astrid Baumann¹, Angela Pakozdi², Andrea Cove-Smith², Debasish Pyne², Michael Sheaff¹ and Ravindra Rajakariar², ¹Barts Lupus Centre, London, United Kingdom, ²Barts Lupus Centre, Barts Health NHS Trust, London, United Kingdom
Background/Purpose: Renal biopsies are considered the gold standard in diagnosing lupus nephritis (LN). ALMS (1), the largest randomized trial in LN, reported the non-inferiority of…
Abstract Number: 173 • 2017 ACR/ARHP Annual Meeting
Applying Urine Proteomics for Discovery of Lupus Nephritis Damage Biomarkers in a Pediatric Cohort
Jessica Turnier¹, Bruce Aronow², Kenneth Greis³, Michael Bennett⁴, Wendy Haffey³, Sherry Thornton⁵, Gaurav Gulati⁶, Michael Wagner⁷, David Witte⁸, Prasad Devarajan⁹ and Hermine I. Brunner¹⁰, ¹Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Computational Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³University of Cincinnati College of Medicine, Cincinnati, OH, ⁴Nephrology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Division of Immunology, Allergy and Rheumatology, University of Cincinnati College of Medicine, Cincinnati, OH, ⁷Biomedical Informatics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁸Pathology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁹Nephrology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ¹⁰Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Non-invasive biomarkers of lupus nephritis (LN) damage are needed to guide treatment decisions and determine risk for kidney failure. Urinary proteomics has advanced as…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.